A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency

Inclusion Criteria: * Iron deficient subjects with stable chronic heart failure (CHF) (NYHA II-III) on optimal background therapy for CHF * Reduced left ventricular ejection fraction * Capable of completing 6 minute walk test * At least 18 years of age and with written informed consent prior to any study specific procedures Exclusion Criteria: * Erythropoietin stimulating agent (ESA) use, IV iron therapy and/or blood transfusion in previous 6 weeks prior to randomisation * Exercise training program(s) in the 3 months prior to screening or planned in the next 6 months * Chronic liver disease and/or elevated liver enzymes * Vitamin B12 and/or serum folate deficiency * Subject is not using adequate contraceptive precautions during the study * Body weight ≤ 35 kg * No other significant cardiac or general disorders that would compromise the ability to give informed consent and/or comply with study procedures